Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Essen – page 69

989 clinical trials in Essen, Germany across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Essen at a glance
989
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

989 trials in Essen

Open in trial search

Malignant melanoma+1

Not recruiting

Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Naporafenib
  • Sponsor:Novartis Pharma AG

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Non-small cell lung cancer

Not recruiting

Study on Continued Ceritinib Treatment for Patients with ALK Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ceritinib
  • Sponsor:Novartis Pharma AG

Neuroendocrine tumour+1

Not recruiting

Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Octreotide
  • Sponsor:Advanced Accelerator Applications

Herpes simplex

Not recruiting

Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Cidofovir
  • Sponsor:AiCuris Anti-infective Cures AG

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Non-small cell lung cancer

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Universitaetsklinikum Essen AöR

Chronic myeloid leukaemia

Not recruiting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Evaluating Higher Dose Nusinersen in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam

Not recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Nusinersen
  • Sponsor:Biogen Idec Research Limited

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Epstein-Barr virus associated lymphoma

Not recruiting

Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ganciclovir Sodium
  • Sponsor:Viracta Therapeutics Inc.

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Essen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic colorectal cancer, breast cancer, and lymphoma treatments. Studies evaluate novel therapeutic combinations and targeted approaches for various cancer types.

  • HER2-positive breast cancer therapies
  • Diffuse Large B-Cell Lymphoma treatments
  • Metastatic prostate cancer interventions

Research includes evaluation of new drug combinations and immunotherapy approaches.

02 Respiratory Medicine

Studies examining preventive treatments for respiratory syncytial virus and related infections. Research focuses on vaccine development and immune response in different age groups.

  • RSV vaccine efficacy studies
  • Human Metapneumovirus research
  • Pneumococcal disease prevention

Emphasis on protecting vulnerable populations including older adults and at-risk individuals.

03 Neurological Disorders

Clinical research addressing Alzheimer's disease and acute cerebral ischemic stroke. Investigations into novel therapeutic approaches and diagnostic tools.

  • Early-stage Alzheimer's treatment
  • Stroke recovery interventions
  • Spinal muscular atrophy therapies

Focus on improving patient outcomes through innovative treatment strategies.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.